Overview

TAP Using Dexmedetomidine and Ropivacaine for Cesarean Section Analgesia

Status:
Not yet recruiting
Trial end date:
2023-10-31
Target enrollment:
Participant gender:
Summary
To evaluate the effect of dexmedetomidine as an adjuvant of ropivacaine in the TAP block on cesarean section parturients under multimodal analgesia, optimize the multimodal analgesia program for cesarean section, and guide perioperative analgesia managemen。This is a single center, double-blind, randomized clinical trial.
Phase:
N/A
Details
Lead Sponsor:
Xijing Hospital
Treatments:
Dexmedetomidine